Trial · NCT05048017
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
NCT05048017, Phase 2, Unknown, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma. Trials, record NCT05048017. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05048017
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
- NCT number
- NCT05048017
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- Hepatocellular Carcinoma, Regorafenib, PD-1 Inhibitor
- Interventions
- Regorafenib, PD-1 inhibitor
- First posted
- 2021-09-17
- Last updated
- 2023-03-29
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | one year | A duration from the date of initial treatment to disease progression (defined by RECIST 1.1) or death of any cause |
| Secondary | Objective Response Rate (ORR) | one year | Proportion of patients whose tumor volume has reached a predetermined value and can maintain a minimum time limit, including complete response and partial response patients |
| Secondary | Complete response (CR) | one year | Disappearance of all target lesions, no appearance of new lesions, and normalization of tumor markers last for at least 4 weeks. |
| Secondary | Partial response (PR) | one year | Sum of the maximum diameters of target lesions is reduced by at least 30%, which lasts for at least 4 weeks. |
| Secondary | Overall survival (OS) | one year | It is the time from when a subject is clearly enrolled to death from any cause. |
| Secondary | Duration of response (DOR) | one year | It is the time from the first-time PR or CR (subject to the earlier one) objectively reported to the first-time disease progression or death. |
| Secondary | Percentage of patients with stable disease (SD) ≥ 4 weeks | one year | It is specifically referred to the percentage of patients with identified SD that can be evaluated for efficacy. |
| Secondary | Progression-free survival rate at 3 months | 6 months | It's the percentage of patients with no disease progression or died from any cause after 3 months of treatment with combination of regorafenib and PD-1 inhibitor in the total number of patients whose efficacy can be evaluated. |
| Secondary | Mortality at 12 months | one year and a half | It's the percentage of patients who died of any cause after 12 months treatment with combination of regorafenib and PD-1 inhibitor in total enrolled patients. |
| Other | Adverse Event (AE) | two years | Definition: Refers to any adverse medical event that occurs in patients receiving medical product treatment or subjects of clinical studies, which may not have a causal relationship with the treatment. AE includes but is not limited to: abnormal laboratory test results; clinically significant symptoms and signs; allergies, etc. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers18
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05048017
GET https://conductscience.org/api/trials/v1/NCT05048017/registered